Successful brentuximab vedotin monotherapy against late relapse of classical Hodgkin lymphoma 6 years after first remission.
Nagashima, Kana
Successful brentuximab vedotin monotherapy against late relapse of classical Hodgkin lymphoma 6 years after first remission. [electronic resource] - Clinical case reports Mar 2020 - 466-468 p. digital
Publication Type: Case Reports; Journal Article
2050-0904
10.1002/ccr3.2688 doi
Successful brentuximab vedotin monotherapy against late relapse of classical Hodgkin lymphoma 6 years after first remission. [electronic resource] - Clinical case reports Mar 2020 - 466-468 p. digital
Publication Type: Case Reports; Journal Article
2050-0904
10.1002/ccr3.2688 doi